A phase II randomized trial, GENOM 009, which analyzed the effects of adjuvant therapy with the combination of BEV + TMZ, showed longer PFS and OS in the TMZ + BEV arm compared to TMZ monotherapy, although the difference did not reach statistical significance.
1
—
—